I heard on Twitter that no one wants to see your “Year in Review.” @lucyboyen, for example, tweeted “I looked at my year in review and thought to myself you know who wants to see that? Absolutely nobody.”
Yes, 2016 was a lousy year for many people and even for the drug industry, but for different reasons. Yet if you look at the numbers, you will find some good news as well. So I feel justified in collecting together this Slideshare “2016 Year in Review” focusing on the many charts and graphs that I have published via Pharma Marketing News, Pharma Marketing Blog, and curated via Pharma Industry News Update. Hope you find it useful.
Click on “Read more” to find a bulleted list with links in case you can’t link to the sources within the embedded presentation below.
- FDA Drug Approvals Up, Up, & Away!
- But Drug Approvals & R&D ROI Drop in 2016!
- Path Taken by Sarepta NOT a Good Model for Other Rare Drug Approvals
- FDA to Device Makers: Want Faster Approval? Then Pay Up!
- Cost to Bring a New Drug to Market is Increasing – Or Is It?
- Vaccines Are Path to Revenue Growth
- Facts About Prescription Drug Spending
- How Much Does Pharma Lose Each Year Due to Medication Nonadherence?
- Overall DTC Ad Spend Ties Record High!
- The Boom in DTC TV Advertising!
- Top 10 Rx TV Ad Spends
- Fair Balance & Adequate Provision in Drug Banner Ads
- Only 1 Top 10 Pharma Spends a Bit More on R&D Than Marketing
- Drugs for Older Americans Rose 15.5% in 2015
- Questions About FDA Regulation of EpiPen Competition
- Tracking Who Makes Money On A Brand-Name Drug
- Content Channel Value as Seen by Docs vs. Pharma
- Only 10% of Docs Prefer Info Direct from Pharma to Make Treatment Decisions
- Physicians Prefer Pharma Info Via Email
- Pharma Sales Reps: Declined & Denied!
- Growth/Decline in Pharma Support of CME
- FDA’s Lax Enforcement Trend Continues
- FDA Enforcement vs. PDUFA Fees Coincidence?
- Dramatic Increase in Drug Adverse Events
- FDA User Fees & the Increase in Serious AERs
- 25 Years of Pharma Criminal & Civil Penalties
- Pharma’s Rep Among Patient Groups at 4-Year High
- Pharma Criminal & Civil Penalty Challenge
- Social Media & the Written Word
